Skip to main content
. 2015 Jun 8;112(27):8278–8283. doi: 10.1073/pnas.1506761112

Fig. 1.

Fig. 1.

LNM (1) and LNM E1 (2) as novel anticancer drug leads via episulfonium ion-mediated DNA alkylation upon complementary activation: (A) reductive activation of 1 by cellular thiols and (B) oxidative activation of 2 by cellular ROS, affording a pair of episulfonium ions that efficiently alkylate the N7 position of deoxyguanosine bases of DNA, thereby causing DNA cleavage and eventual cell death.